Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inulin + lactiplantibacillus plantarum LPm77
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A synbiotic combination of inulin (a dietary prebiotic fiber) and Lactiplantibacillus plantarum LPm77 (a probiotic bacterial strain). This formulation acts by modulating the gut-liver axis, enhancing beneficial gut microbiota, restoring intestinal barrier function, regulating bile acid metabolism, and favorably affecting metabolic and immune parameters. In preclinical models of type 2 diabetes mellitus, the synbiotic reduces hyperglycemia, insulin resistance, and hepatic steatosis. Mechanistically, inulin promotes the colonization and activity of L. plantarum LPm77, while the combination increases the biosynthesis of tauro-ursodeoxycholic acid (TUDCA), activates the bile acid receptor TGR5, and suppresses inflammatory pathways (notably TLR4–NF-κB) associated with metabolic dysregulation[1][3].
02
Targets
TLR4 (Toll-like receptor 4)GPBAR1NF-κB
Beyond the preview
Go deeper on inulin + lactiplantibacillus plantarum LPm77.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inulin + lactiplantibacillus plantarum LPm77.